Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757747 | 1.00 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL996547 | 1.00 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL996546 | 1.00 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL2735605 | 1.00 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL10405962 | 1.00 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL95535 | 1.00 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL14658031 | 0.97 | LMNA (0.65) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL16690502 | 0.92 | LMNA (0.65) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL10844984 | 0.89 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL10535023 | 0.89 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034571-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2025-01-30 | — | — | US | disclosed |
| US-12129467-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-10-29 | — | — | US | disclosed |
| US-20240316206-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-09-26 | — | — | US | disclosed |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-06 | — | — | US | disclosed |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-05-09 | — | — | US | disclosed |
| CN-114409564-B | Compound containing trityl structure and application thereof | 广州同隽医药科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-03-28 | — | — | US | disclosed |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-01 | — | — | US | disclosed |
| US-6562398-B1 | Ionically and/or electrically insulating surface of such as gallium arsenide; attaching self assembling monolayer membrane having bonding functional groups | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 2003-05-13 | — | — | US | disclosed |
| WO-2003023877-A2 | SURFACE MODIFYING LAYERS FOR ORGANIC THIN FILM TRANSISTORS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-03-20 | — | — | WO | disclosed |
| US-6433359-B1 | SURFACE MODIFIED WITH ORGANIC COMPOUND | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-13 | — | — | US | disclosed |
| EP-1090077-A1 | MOLECULAR COATINGS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999061531-A1 | MOLECULAR COATINGS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-12-02 | — | — | WO | disclosed |
| EP-0050327-B1 | PHOSPHOLIPIDS THAT CONTAIN SULPHUR, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1984-06-20 | — | — | EP | disclosed |
| US-4444766-A | ANTITUMOR | BOEHRINGER MANNHEIM GMBH (DE) | 1984-04-24 | — | — | US | disclosed |
| EP-0050327-A1 | Phospholipids that contain sulphur, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1982-04-28 | — | — | EP | disclosed |
| US-4017514-A | Hypolipidemic agents | RICHARDSON-MERRELL INC. (US) | 1977-04-12 | — | — | US | disclosed |
| US-4011333-A | SUBSTITUTED THIOPHENECARBOXYLIC ACID AND ESTERS AS HYPOLIPIDEMIC AGENTS | RICHARDSON-MERRELL INC. (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | LMNA 758/4885BLM 2897/4885PTPN1 2028/4885 |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | LMNA 177/4885BLM 1596/4885PTPN1 1636/4885 |
| US-20250034571-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | LMNA 177/4885BLM 1596/4885PTPN1 1636/4885 |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | LMNA 758/4885BLM 2897/4885PTPN1 2028/4885 |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | LMNA 177/4885BLM 1596/4885PTPN1 1636/4885 |
| US-20240316206-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | LMNA 758/4885BLM 2897/4885PTPN1 2028/4885 |
| US-12129467-B2 | Non-liposomal systems for nucleic acid delivery | SNRPE, NPC1L1, LIPA | LMNA 177/4885BLM 1596/4885PTPN1 1636/4885 |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | LMNA 793/4885BLM 3014/4885PTPN1 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.